Evidence map›Paper›PMID 33823854›Full record

ArticleMolecular cancer2021

An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma.

Francesca Reggiani, Elisabetta Sauta, Federica Torricelli, Eleonora Zanetti, Elena Tagliavini, Giacomo Santandrea, Giulia Gobbi, Giovanna Damia, Riccardo Bellazzi, Davide Ambrosetti and 2 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Francesca Reggiani *Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, via Risorgimento 80, 42123, Reggio Emilia, Italy.
Elisabetta Sauta *Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, via Risorgimento 80, 42123, Reggio Emilia, Italy.
Federica TorricelliLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, via Risorgimento 80, 42123, Reggio Emilia, Italy.
Eleonora ZanettiPathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Elena TagliaviniPathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Giacomo SantandreaPathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Giulia GobbiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, via Risorgimento 80, 42123, Reggio Emilia, Italy.
Giovanna DamiaLaboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Riccardo BellazziDepartment of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.
Davide AmbrosettiDepartment of Pharmacy and Biotechnology (FaBit), University of Bologna, Bologna, Italy.
Alessia CiarrocchiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, via Risorgimento 80, 42123, Reggio Emilia, Italy.
Valentina SancisiLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, via Risorgimento 80, 42123, Reggio Emilia, Italy. valentina.sancisi@ausl.re.it.ORCID 0000-0003-4357-1228
Azienda Sanitaria Unità Locale di Reggio Emilia · ITUniversity of Pavia · ITMario Negri Institute for Pharmacological Research · ITUniversity of Bologna · ITUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorGenomicsMutationAdenocarcinoma of LungAntineoplastic AgentsDisease ManagementDisease SusceptibilityGene Knockout TechniquesHumansHypoxia-Inducible Factor 1, alpha SubunitHypoxia-Inducible Factor-Proline DioxygenasesModels, BiologicalMolecular Targeted TherapyProto-Oncogene Proteins p21(ras)Antineoplastic AgentsBiomarkers, TumorEGLN1 protein, humanHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitHypoxia-Inducible Factor-Proline DioxygenasesKRAS protein, humanProto-Oncogene Proteins p21(ras)CRISPR/Cas9 screeningEGLN1HIF1AKRASLung cancer

Identifiers

PMID33823854
PMCPMC8022436
OpenAlexW3148973731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.